As proposed for alternatively spliced isoforms of PD-L1 in melanoma [81], such variants could influence the efficacy of ICIs if they prevent ICI binding to PD-1/PD-L1, consequently diminishing their therapeutic effects. This evidence concerns the gene CD274 and melanoma.